Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Université Laval

$140,000.00

Deep mutational scanning for collateral sensitivity of antifungal drug resistance

FY 2024-25

Summary
Pathogenic fungi form a growing - yet neglected - public health threat, especially because very few antifungal drugs have been developed while the incidence of antifungal drug resistance in harmful fungi, particularly Candida auris, is rising worldwide. Candida auris is a novel pathogenic yeast species, described in 2009 and known for its ability to quickly develop resistance to multiple antifungal drugs, making infections difficult to treat and control. This research aims to exploit a recently discovered evolutionary phenomenon called "collateral sensitivity", where resistance to one drug increases sensitivity to another, to redesign antifungal treatments that outmaneuver resistance. By using advanced genetic techniques, we will systematically map how mutations in the most important antifungal drug target, influence resistance and collateral sensitivity to various other drugs, including novel promising compounds, in Candida auris. The goal is to identify which are the most optimal drugs to combat each resistance mutation and make a genetic-based model to propose the best treatment options that can overcome resistance and improve patient outcomes. Moreover, our analyses will enable more in-depth insight into the mechanism of drug-target binding, which can inspire future drug optimization. This research is highly innovative and crucial for developing better treatments and combating drug-resistant fungal infections, benefiting public health in Canada and globally.
Program
CIHR Fellowship
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
513743
Name
Carolus Hans
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Deep mutational scanning for collateral sensitivity of antifungal drug resistance
Programtype2
Fellowship Programs
Orgnameinp2
Université Laval
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antifungal Drug Resistance,; Antifungal Drugs; Antimicrobials And Resistance; Candida Auris; Collateral Sensitivity; Deep Mutational Scanning; Echinocandins; Fungi; Modelling; Molecular Genetics
Abstract
Pathogenic fungi form a growing - yet neglected - public health threat, especially because very few antifungal drugs have been developed while the incidence of antifungal drug resistance in harmful fungi, particularly Candida auris, is rising worldwide. Candida auris is a novel pathogenic yeast species, described in 2009 and known for its ability to quickly develop resistance to multiple antifungal drugs, making infections difficult to treat and control. This research aims to exploit a recently discovered evolutionary phenomenon called "collateral sensitivity", where resistance to one drug increases sensitivity to another, to redesign antifungal treatments that outmaneuver resistance. By using advanced genetic techniques, we will systematically map how mutations in the most important antifungal drug target, influence resistance and collateral sensitivity to various other drugs, including novel promising compounds, in Candida auris. The goal is to identify which are the most optimal drugs to combat each resistance mutation and make a genetic-based model to propose the best treatment options that can overcome resistance and improve patient outcomes. Moreover, our analyses will enable more in-depth insight into the mechanism of drug-target binding, which can inspire future drug optimization. This research is highly innovative and crucial for developing better treatments and combating drug-resistant fungal infections, benefiting public health in Canada and globally.
Competitiondate
202410
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Carolus, Hans
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~